Search

Your search keyword '"Zander T"' showing total 760 results

Search Constraints

Start Over You searched for: Author "Zander T" Remove constraint Author: "Zander T"
760 results on '"Zander T"'

Search Results

2. Endoluminal occlusion devices: technology update

8. 43O A dose-escalation study of TNO155 (TN) in combination with spartalizumab (SPA) or ribociclib (RIB) in adults with advanced solid tumors

9. Home parenteral nutrition (HPN) using individually compounded PN via A 7/8/9-Multi-chamber system versus PN via 2/3-chamber bags in subjects with metastatic or localized solid tumors requiring HPN - The IKF-010 Pekannuss trial

10. Hospital 2090: How Nowadays Technology Could Contribute to the Future of the Hospitals

12. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

13. SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY

16. P09.12 Hereditary homozygosity and allelic imbalance of HLA as common immune escape mechanisms in esophageal adenocarcinoma

18. Utilizing Secondary Input from Passive Brain-Computer Interfaces for Enhancing Human-Machine Interaction

21. Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts

22. HEREDITARY HOMOZYGOSITY AND ALLELIC IMBALANCE OF HLA AS COMMON IMMUNE ESCAPE MECHANISMS IN ESOPHAGEAL ADENOCARCINOMA

27. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

28. Integrated Genomic Profiling of Endometrial Carcinoma Associates Aggressive Tumors with Indicators of PI3 Kinase Activation

29. 1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

34. PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES

35. SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK

36. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

37. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

38. Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus

45. MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab: ID 439

49. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

50. impact on future treatment strategies

Catalog

Books, media, physical & digital resources